Gilead To Buy PepStar's IBD Investigational Oral IL-23R Inhibitor Program For $1.275 Bln Cash

Gilead Sciences (GILD) agreed to buy PepStar's investigational oral IL-23R inhibitor program, including HCXT-2001, for $1.275 billion in cash. The deal is expected to close in Q4 2026 and reduce Gilead's EPS by $0.79-$0.83 in that quarter. The acquisition expands Gilead's portfolio for inflammatory and immune-mediated diseases. PepStar is a privately held biotech firm.

Original reporting
Published Oct 23, 2026, 7:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 7:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$GILD
Bearish
high confidence
Mentioned
$GILD
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$GILDBearishHigh
01

Why it matters

The acquisition adds a novel modality to Gilead's portfolio but introduces a near‑term earnings drag.

02

Market read

The deal is material for Gilead's valuation and may set a precedent for cash acquisitions in the immunology space.

03

What to watch

Potential synergies with Gilead's existing immunology portfolio and future revenue streams are not reflected in the immediate EPS impact.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Gilead is expanding its inflammatory disease pipeline by acquiring an oral macrocyclic peptide candidate currently in Phase 1.

Company-level read

Ticker impact

$GILDBearishHigh confidence
Context

Gilead announced a $1.275 billion cash acquisition of PepStar's oral IL‑23R inhibitor program, a material M&A event.

Expected impact

downward pressure as the market prices in the EPS dilution

Evidence & confidence

A large cash outlay and explicit EPS reduction guidance create a clear downside catalyst.

Market effects

Biopharma M&A activity may lift peer valuations as consolidation accelerates.

U.S. biotech sector sees heightened scrutiny on cash‑heavy deals.

Large‑scale drug pipeline acquisitions influence global investors tracking immunology therapeutics.

Counterpoint

If the IL‑23R program shows strong Phase 2 data, the long‑term upside could outweigh short‑term EPS hit.

Key entities

  • Gilead Sciences, Inc.

    US‑listed biopharma acquiring the IL‑23R program.

  • PepStar Therapeutics Ltd.

    Private biotech selling its oral IL‑23R inhibitor program.

Related articles

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.

$GSKMed

The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs

The Liver Meeting 2026 highlighted advancements in hepatitis delta, PBC, and MASH treatments. Vir Biotechnology's elebsiran and Mirum Pharmaceuticals' brelovitug showed promising phase 3 results for hepatitis delta, with regulatory submissions expected in 2027. GSK's bepirovirsen received FDA approval for hepatitis B. Merck's efinopegdutide and Altimmune's pemvidutide showed potential in MASH treatment. Real-world data indicated cost concerns with MASH therapies.

$GILDMed

Phase 3 Data Back ALP Normalization as Treatment Goal in PBC

Phase 3 trials show elafibranor (Ipsen) and seladelpar (Gilead Sciences) effectively normalize ALP levels in PBC patients. Both drugs were approved in 2024 for inadequate UDCA response. Trials reported significant ALP reduction and normalization rates, with safety profiles similar to placebo.

$GILDMed

Invikafusp Alfa Plus Sacituzumab Govitecan Generates Responses in Metastatic TNBC and HR+/HER2– Breast Cancer

A phase 1b/2 trial showed a 28% ORR in TNBC and 25% in HR+/HER2– breast cancer patients treated with invikafusp alfa and sacituzumab govitecan. The combination demonstrated preliminary antitumor activity with no new safety signals. Sacituzumab govitecan is FDA-approved for these indications. The trial's lead author noted the potential for deeper immune responses in historically resistant tumors.

$GILDHigh

Gilead Pays a $3.28 Annual Dividend Despite Negative Earnings. Is It Safe?

Gilead Sciences (GILD) raised its quarterly dividend to $0.82, with a full-year payout of $3.28, despite a negative trailing EPS of -$3.13. The company's third-quarter revenue was $8.30B, with HIV sales up 18% and Yeztugo sales at $305M. Free cash flow covered the dividend 4.6x, and adjusted EPS is expected to be $8.75-$9.10. Risks include Medicare pricing impacts and acquisition-related charges.